Tailoring a Plasmodium vivax vaccine to enhance efficacy through a combination of a CSP virus-like particle and TRAP viral vectors
Vivax malaria remains one of the most serious and neglected tropical diseases, with 132 to
391 million clinical cases per year and 2.5 billion people at risk of infection. A vaccine …
391 million clinical cases per year and 2.5 billion people at risk of infection. A vaccine …
Prime-boost vaccination with recombinant protein and adenovirus-vector expressing Plasmodium vivax circumsporozoite protein (CSP) partially protects mice against …
TM De Camargo, EO De Freitas, AM Gimenez… - Scientific reports, 2018 - nature.com
Vaccine development against Plasmodium vivax malaria lags behind that for Plasmodium
falciparum. To narrow this gap, we administered recombinant antigens based on P. vivax …
falciparum. To narrow this gap, we administered recombinant antigens based on P. vivax …
Rational development of a protective P. vivax vaccine evaluated with transgenic rodent parasite challenge models
AM Salman, E Montoya-Díaz, H West, A Lall… - Scientific reports, 2017 - nature.com
Abstract Development of a protective and broadly-acting vaccine against the most widely
distributed human malaria parasite, Plasmodium vivax, will be a major step towards malaria …
distributed human malaria parasite, Plasmodium vivax, will be a major step towards malaria …
Protective Malaria Vaccine in Mice Based on the Plasmodium vivax Circumsporozoite Protein Fused with the Mumps Nucleocapsid Protein
RF Marques, AM Gimenez, E Aliprandini, JT Novais… - Vaccines, 2020 - mdpi.com
Plasmodium vivax is the most common species of human malaria parasite found outside
Africa, with high endemicity in Asia, Central and South America, and Oceania. Although …
Africa, with high endemicity in Asia, Central and South America, and Oceania. Although …
A universal vaccine candidate against Plasmodium vivax malaria confers protective immunity against the three PvCSP alleles
AM Gimenez, AM Salman, RF Marques… - Scientific Reports, 2021 - nature.com
Malaria is a highly prevalent parasitic disease in regions with tropical and subtropical
climates worldwide. Among the species of Plasmodium causing human malaria, P. vivax is …
climates worldwide. Among the species of Plasmodium causing human malaria, P. vivax is …
Phase 1/2a Trial of Plasmodium vivax Malaria Vaccine Candidate VMP001/AS01B in Malaria-Naive Adults: Safety, Immunogenicity, and Efficacy
JW Bennett, A Yadava, D Tosh… - PLoS neglected …, 2016 - journals.plos.org
Background A vaccine to prevent infection and disease caused by Plasmodium vivax is
needed both to reduce the morbidity caused by this parasite and as a key component in …
needed both to reduce the morbidity caused by this parasite and as a key component in …
Immunogenicity of a prime-boost vaccine containing the circumsporozoite proteins of Plasmodium vivax in rodents
LH Teixeira, CA Tararam, MO Lasaro… - Infection and …, 2014 - Am Soc Microbiol
Plasmodium vivax is the most widespread and the second most prevalent malaria-causing
species in the world. Current measures used to control the transmission of this disease …
species in the world. Current measures used to control the transmission of this disease …
A Multistage Formulation Based on Full-Length CSP and AMA-1 Ectodomain of Plasmodium vivax Induces High Antibody Titers and T-cells and Partially Protects Mice …
LC Lima, RF Marques, AM Gimenez, KS Françoso… - Microorganisms, 2020 - mdpi.com
Infections with Plasmodium vivax are predominant in the Americas, representing 75% of
malaria cases. Previously perceived as benign, malaria vivax is, in fact, a highly debilitating …
malaria cases. Previously perceived as benign, malaria vivax is, in fact, a highly debilitating …
Evaluation of immune responses to a Plasmodium vivax CSP-based recombinant protein vaccine candidate in combination with second-generation adjuvants in mice
JM Lumsden, S Nurmukhambetova, JH Klein… - Vaccine, 2012 - Elsevier
Plasmodium vivax is the major cause of malaria outside of sub-Saharan Africa and causes
morbidity and results in significant economic impact in developing countries. In order to …
morbidity and results in significant economic impact in developing countries. In order to …
Construction and immunogenicity of DNA vaccine plasmids encoding four Plasmodium vivax candidate vaccine antigens
WO Rogers, K Gowda, SL Hoffman - Vaccine, 1999 - Elsevier
Plasmodium vivax is the second most common agent of human malaria. Although infection
is rarely fatal, it nonetheless imposes a significant burden of illness in endemic areas. A …
is rarely fatal, it nonetheless imposes a significant burden of illness in endemic areas. A …